Massachusetts women’s health company Hologic (NSDQ:HOLX) rang in Breast Cancer Awareness Month with the release of registry data from the MammoSite trial, a 7-year study of more than 1,400 patients treated with breast brachytherapy.
MammoSite therapy is a breast-conserving treatment that delivers targeted radiation to areas deemed most likely for the re-emergence of cancerous growth. The final analysis of patients in Hologic’s registry found low rates of local recurrent, greater than 90% long-term cosmesis (retention of aesthetic appearance) and less than 10% toxicity, according to a company statement.
The findings, including an analysis by the American Society of Breast Surgeons, largely confirmed previous results from MammoSite studies, showing that the therapy compares favorably to other forms of accelerated partial breast irradiation, Hologic said.
"The American Society of Breast Surgeons MammoSite Registry Trial continues to represent one of the most pivotal studies available in defining the safety and efficacy of brachytherapy based partial breast irradiation," lead author Dr. Chirag Shah of Summa Health System said in prepared remarks. "The final analysis of this trial not only confirmed the efficacy of brachytherapy based partial breast irradiation, but demonstrated that rates of toxicity following treatment remain low and favorable, in line with previously reported toxicity rates using whole breast irradiation."
That’s more good news for Hologic, which recently landed the 4th year of a contract with the Dept. of Defense worth $32.2 million.
